Technical Analysis for COLL - Collegium Pharmaceutical, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Multiple of Ten Bearish | Other | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New Downtrend | Bearish | -2.28% | |
| Calm After Storm | Range Contraction | -2.28% | |
| Inside Day | Range Contraction | -2.28% | |
| Oversold Stochastic | Weakness | -2.28% | |
| Multiple of Ten Bullish | Other | -1.99% | |
| Below Lower BB | Weakness | -1.99% |
| Alert | Time |
|---|---|
| Down 3% | 2 days ago |
| Fell Below Lower Bollinger Band | 2 days ago |
| 60 Minute Opening Range Breakdown | 2 days ago |
| Down 2 % | 2 days ago |
| Down 1% | 2 days ago |
Get a Trading Sidekick!
- Earnings date: 11/07/2024
Collegium Pharmaceutical, Inc. Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its lead product candidate is Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication. The company is also developing COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-196, a morphine formulation for the treatment of pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for the treatment of attention deficit hyperactivity disorder. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Disease Pain Organic Compounds Chemical Compounds Euphoriants Opioids Chronic Pain Ethers Platform Technology Attention Deficit Hyperactivity Disorder Morphinans Hyperactivity Disorder Methylphenidate Treatment Of Chronic Pain Morphine Phenols Hydrocodone Oxycodone Oxymorphone Treatment Of Attention Deficit Hyperactivity Disorder
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 42.2873 |
| 52 Week Low | 25.13 |
| Average Volume | 410,256 |
| 200-Day Moving Average | 35.47 |
| 50-Day Moving Average | 36.36 |
| 20-Day Moving Average | 33.57 |
| 10-Day Moving Average | 32.11 |
| Average True Range | 1.53 |
| RSI (14) | 27.01 |
| ADX | 27.6 |
| +DI | 12.51 |
| -DI | 35.43 |
| Chandelier Exit (Long, 3 ATRs) | 35.22 |
| Chandelier Exit (Short, 3 ATRs) | 33.77 |
| Upper Bollinger Bands | 37.54 |
| Lower Bollinger Band | 29.59 |
| Percent B (%b) | 0.0 |
| BandWidth | 23.68 |
| MACD Line | -1.78 |
| MACD Signal Line | -1.39 |
| MACD Histogram | -0.3906 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 31.80 | ||||
| Resistance 3 (R3) | 31.91 | 31.28 | 31.43 | ||
| Resistance 2 (R2) | 31.28 | 30.71 | 31.23 | 31.31 | |
| Resistance 1 (R1) | 30.43 | 30.37 | 30.12 | 30.32 | 31.18 |
| Pivot Point | 29.80 | 29.80 | 29.64 | 29.75 | 29.80 |
| Support 1 (S1) | 28.95 | 29.23 | 28.64 | 28.84 | 27.98 |
| Support 2 (S2) | 28.32 | 28.89 | 28.27 | 27.85 | |
| Support 3 (S3) | 27.47 | 28.32 | 27.73 | ||
| Support 4 (S4) | 27.36 |
